

CERTIFICATE

Survey of 17 April 2026

You have fulfilled the requirements of the External Quality Assessment with the following analysis

HLA Diagnostics - HLA-DQ (772):

Validity 12 months:

HLA DQA1*05

HLA DQB1*02

HLA DQB1*03:02

(R) analysis is subject to the RiliBÄK

Customer:

10074873

Clinomics Europe Kft.

Molekularis Genetikai Laboratorium

Dr. Biro Orsolya

Mihalkovics u. 10.

1094 Budapest

Düsseldorf, 04 May 2026



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Dr.-Ing. Nils Lachmann
(Adviser)

CERTIFICATE OF PARTICIPATION

Survey of 17 April 2026

You have participated in the External Quality Assessment with the following analysis

HLA Diagnostics - HLA-DQ (772):

HLA DQA1*05
HLA DQB1*02
HLA DQB1*03:02

(R) analysis is subject to the RiliBÄK

Customer:
10074873
Clinomics Europe Kft.
Molekularis Genetikai Laboratorium
Dr. Biro Orsolya
Mihalkovics u. 10.
1094 Budapest

Düsseldorf, 04 May 2026



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Dr.-Ing. Nils Lachmann
(Adviser)

Listing and evaluation of the results

10074873: Clinomics Europe Kft.
Molekularis Genetikai Laboratorium
Dr. Biro Orsolya

Survey of 17 April 2026

Adviser: **Dr.-Ing. Nils Lachmann**
Charité-Universitätsmedizin Berlin, ZTB-Zentrum für Transfusionsmedizin und Zelltherapie Berlin gGmbH, Gewebetypisierung am Campus Virchow-Klinikum Augustenburger Platz 1 13353 Berlin
Tel.: +49 30 450 665 098
Fax: +49 30 450 553 918
Mail: nils.lachmann@instand-ringversuch.de

772

HLA Diagnostics - HLA-DQ

Analyte	Sample 772A- 260323	Method	Manu- facturer	Device	Your specification(s)	Correct specification(s)	TV- Type	Meets criteria
HLA DQA1*05	-01	388	BDR		negative	negative	M	+
	-02				positive	positive	M	+
HLA DQB1*02	-01	388	BDR		negative	negative	M	+
	-02				positive	positive	M	+
HLA DQB1*03:02	-01	388	BDR		negative	negative	M	+
	-02				negative	negative	M	+

** BRAVO **

Individual summary of results

10074873: Clinomics Europe Kft.
Molekularis Genetikai Laboratorium
Dr. Biro Orsolya

Survey of 17 April 2026

772

HLA Diagnostics - HLA-DQ

HLA DQA1*05 (N = 76, Rate of success: 100%)

Sample 772A-260323-01

Collective	negative	total
all methods	76 ●	76

Sample 772A-260323-02

Collective	positive	total
all methods	76 ●	76

The point corresponds to the correct result, the horizontal bar corresponds to your specification, the vertical bar corresponds to your collective

HLA DQB1*02 (N = 76, Rate of success: 98,7%)

Sample 772A-260323-01

Collective	negative	total
all methods	76 ●	76

Sample 772A-260323-02

Collective	negative	positive	total
all methods	1	75 ●	76

The point corresponds to the correct result, the horizontal bar corresponds to your specification, the vertical bar corresponds to your collective

HLA DQB1*03:02 (N = 76, Rate of success: 97,4%)

Sample 772A-260323-01

Collective	negative	total
all methods	76 ●	76

Sample 772A-260323-02

Collective	negative	positive	total
all methods	74 ●	2	76

The point corresponds to the correct result, the horizontal bar corresponds to your specification, the vertical bar corresponds to your collective